---
title: "Sanara MedTech Inc. (SMTI.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/SMTI.US.md"
symbol: "SMTI.US"
name: "Sanara MedTech Inc."
industry: "Health Care Supplies"
datetime: "2026-05-19T21:39:26.759Z"
locales:
  - [en](https://longbridge.com/en/quote/SMTI.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/SMTI.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/SMTI.US.md)
---

# Sanara MedTech Inc. (SMTI.US)

## Company Overview

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical solutions to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns. It also develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY Tissue Repair Graft(FORTIFY TRG), a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; BiFORM, an osteoconductive, bioactive, porous implant that allows bony ingrowth across the graft site and it can be used as a strip or molded into a putty to fill a bone defect; ACTIGEN Inductive Bone Matrix, a naturally derived, differentiated allograft matrix with robust handling properties;  ALLOCYTE Plus, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers; and TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement. The company has a license agreement with Rochal to develop, market, and sell antimicrobial products that include BIASURGE Advanced Surgical Solution, BIAKOS Antimicrobial Wound Gel, and BIAKOS Antimicrobial Skin and Wound Cleanser for the prevention and treatment of microbes on the human body.

| Item | Detail |
|------|--------|
| Industry | Health Care Supplies |
| Exchange | US Market |
| Website | [anaramedtech.com](https://anaramedtech.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:14.000Z

**Overall: C (0.51)**

**Industry**: Health Care Supplies

| Metric | Value |
|--------|-------|
| Industry Ranking | 24 / 45 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 17.38% |  |
| Net Profit YoY | -193.82% |  |
| P/B Ratio | 28.54 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 200616530.73 |  |
| Revenue | 107482420.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 2.89% | C |
| Profit Margin | -31.24% | E |
| Gross Margin | 93.08% | A |
| Revenue YoY | 17.38% | B |
| Net Profit YoY | -193.82% | E |
| Total Assets YoY | -28.12% | E |
| Net Assets YoY | -80.86% | E |
| Cash Flow Margin | -18.82% | D |
| OCF YoY | 17.38% | B |
| Turnover | 1.30 | A |
| Gearing Ratio | 89.87% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Sanara MedTech Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "17.38%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-193.82%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "28.54",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "200616530.73",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "107482420.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "2.89%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "-31.24%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "93.08%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "17.38%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "-193.82%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-28.12%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-80.86%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-18.82%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "17.38%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "1.30",
          "rating": "A"
        },
        {
          "name": "Gearing Ratio",
          "value": "89.87%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -5.97 | 36/45 | - | - | - |
| PB | 28.54 | 37/45 | 30.53 | 25.98 | 7.10 |
| PS (TTM) | 1.87 | 19/45 | 2.84 | 2.20 | 1.74 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Essilor (ESLOY.US) | B | B | C | B | B | B |
| 02 | HOYA Corporation (HOCPY.US) | A | C | B | A | B | B |
| 03 | Align (ALGN.US) | B | C | B | B | C | B |
| 04 | Lantheus (LNTH.US) | A | C | B | C | C | B |
| 05 | Merit Medical (MMSI.US) | B | B | B | C | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-12T04:00:00.000Z

Total Analysts: **2**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 2 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 22.72 |
| Highest Target | 36.00 |
| Lowest Target | 32.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/SMTI.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/SMTI.US/norm.md)
- [Related News](https://longbridge.com/en/quote/SMTI.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/SMTI.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**